NewEdge Wealth LLC Invests $1.34 Million in Natera, Inc. $NTRA

NewEdge Wealth LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,928 shares of the medical research company’s stock, valued at approximately $1,338,000.

Several other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. BlackRock Inc. bought a new position in shares of Natera during the 2nd quarter valued at about $2,962,770,000. Wellington Management Group LLP grew its stake in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp grew its stake in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after purchasing an additional 72,087 shares during the last quarter. Finally, Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTRA. Barclays restated an “overweight” rating and set a $340.00 target price on shares of Natera in a report on Friday, August 7th. Wolfe Research started coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target on the stock. Guggenheim increased their price objective on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Piper Sandler lifted their target price on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 3,076 shares of Natera stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares in the company, valued at approximately $26,611,561.83. The trade was a 2.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the transaction, the insider directly owned 183,774 shares in the company, valued at $49,249,594.26. The trade was a 0.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 181,045 shares of company stock valued at $41,330,968 in the last 90 days. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

Natera stock opened at $332.03 on Friday. The firm’s 50 day simple moving average is $274.24 and its 200-day simple moving average is $229.39. The company has a market cap of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $333.56.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the firm earned ($0.74) EPS. The firm’s quarterly revenue was up 37.7% on a year-over-year basis. On average, analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.